ONC206: Dose 1

Phase 2Small molecule

Jazz Pharmaceuticals

ONC206: Dose 1 is one of 57 small molecule programs targeting Paraganglioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParagangliomaActive, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Paraganglioma

#DrugCompanyPhaseTrials

Kisqali

Erivedge

Afinitor

Vimpat

Thalomid

Velban

Camptosar

Keppra

Taxol

Tibsovo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Paraganglioma

NCT07282587

Clinical

Trials by Indication[1]

Paraganglioma1 trial

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT07282587·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ONC206: Dose 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ONC206: Dose 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ONC206: Dose 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Jazz Pharmaceuticals

ONC206: Dose 1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Paraganglioma1 trial

References

Drug Info

Quick Facts

Related News